highlight the new recommendations in the updated guidelines and discuss the evidence supporting the changes. This summary will highlight the class (strength) of each recommendation as well as the level (quality) of supporting evidence (Table 1 ) and how these have been modified in the 2017 updated guidelines.
Endocarditis Prophylaxis
Endocarditis remains a serious problem for patients with VHD. In the updated 2017 valve guidelines, the patients recommended to receive antibiotic prophylaxis preceding dental procedures remain in alignment with the AHA guidelines published in 2007, 5 in which prophylaxis is limited to only the highest-risk individuals (Table 2 ). Infective endocarditis (IE) is a rare but devastating condition, with mortality rates of 16% at 30 days and 40% at 1 year. 6, 7 Antibiotic prophylaxis is reliant on the idea that certain healthcare-related procedures have increased rates of transient bacteremia, and patients with certain conditions or prosthetic materials are at increased risk of infection.
Evidence for the effectiveness of antibiotic prophylaxis is conflicting. A 2013 Cochrane study that included studies between 1946 and 2013 evaluated the effect on outcomes of antibiotic prophylaxis preceding dental procedures. This analysis was inconclusive about the effectiveness of antibiotic prophylaxis preceding dental procedures for the prevention of IE. 8 Incidence of IE has steadily increased in the United States since 2000, 9 but data are conflicting on whether this trend is related to the more-restricted recommendation from the 2007 AHA/ACC guideline revisions. 10, 11 The updated 2017 ACC/ AHA valve guideline recommendations still include antibiotic prophylaxis for high-risk groups, but with a weakened level of evidence (B to CL-D). However, maintenance of the best oral hygiene to minimize seeding is emphasized. Also new in the updated guidelines is the emerging evidence that patients with prosthetic material after cardiac repair, such as annuloplasty rings and chords, have higher rates of infection than those with repairs without foreign material and have higher mortality. 12, 13 In addition, patients who undergo transcatheter aortic valve replacement (TAVR) are at equal or higher risk of IE compared with those that undergo surgical aortic valve replacement (SAVR). 14 As a result, such individuals are included in the list of patients eligible for antibiotic prophylaxis preceding dental procedures.
Anticoagulation for Atrial Fibrillation With VHD
In the 2014 ACC/AHA valve guidelines, the recommendation for anticoagulation for stroke prophylaxis in patients with atrial fibrillation (AF) was limited to those with mitral stenosis. Recommendations for patients with other valve disorders were not addressed. The 2017 updated guidelines now include anticoagulation recommendations for a broader spectrum of valvular disorders (Table 3) . Data from multiple new randomized control trials (RCTs) evaluating the effectiveness of the direct oral anticoagulants (DOACs) for stroke prophylaxis in AF are now available. [15] [16] [17] These new agents have broadened the anticoagulation options for a large number of patients. However, recommendations for the use of these agents in patients with VHD were previously not addressed. Subgroup analysis of the patients with VHD in the major DOAC trials all noted a similar or increased risk for thromboembolism in this population. [15] [16] [17] Additionally, efficacy and safety of DOACs was similar to that of warfarin in this population. Notably, valvular exclusion criteria differed between trials, but significant mitral stenosis, valve disease requiring intervention, and mechanical heart valves were generally excluded.
The CHA 2 DS 2 -VASc score was also incorporated in the 2017 updated guidelines, in alignment with modern AF management. 18 A retrospective cohort analysis of 73 538
patients assessed risk factors associated with thromboembolism and found that the use of CHA 2 DS 2 -VASc improved identification of low-and high-risk populations. 19 For those with a score of 2 or greater, anticoagulation is recommended. Those with bioprosthetic valves and valve repair are considered increased risk and should be anticoagulated regardless of score. The 2017 updated guidelines recommend the use of a DOAC as an alternative to vitamin K antagonists (VKAs) in patients with AF and native aortic valve disease, tricuspid valve disease, and mitral regurgitation (MR) and a CHA 2 DS 2 -VASc score of 2 or greater (Class IIa, C-LD).
In rheumatic mitral stenosis with AF, the 2017 updated guidelines continue to recommend VKAs as the agents of choice, 20 given that this population has been excluded from the RCTs with DOACs. Although not recommended for therapy, a retrospective analysis of patients with rheumatic and nonrheumatic mitral stenosis showed similar rates of stroke and bleeding in DOAC and VKA patients. 21 
Aortic Stenosis
In the 2104 AHA/ACC valve guidelines, there was recognition for the role of percutaneous interventions for treatment of severe, symptomatic aortic stenosis (AS) in and as an alternative to surgery for those with high surgical risk (Class IIa, LOE B). In the updated 2017 guidelines, the recommendation for TAVR in both high-and prohibitive-risk patients is now a Class 1, LOE A (Table 4) . This change is supported by multiple high-quality RCTs with multiyear follow-up that showed nonsignificant differences in mortality between the TAVR and SAVR in these groups. 22 
Mitral Regurgitation
The 2014 AHA/ACC valve guidelines stressed the importance of identifying the mechanism of MR given that management and outcomes differ between chronic primary and secondary MR (Figures 1 and 2 ). Additionally, in recognition of the increased risk of adverse outcomes with smaller effective regurgitant orifice 29 in secondary MR, the 2014 guidelines defined severe MR using a lower quantification threshold for secondary MR. This led to a great deal of confusion in the imaging community in how to precisely grade MR. As a result, in the updated 2017 guidelines, quantification of MR severity was modified so that both primary and secondary MR are graded similarly. Specifically, for both primary and secondary MR, severe MR is defined as the effective regurgitant orifice ≥0.4 cm 2 and regurgitant volume to ≥60 mL. However, careful recognition of the adverse outcomes observed with lower effective regurgitant orifice in secondary MR remains important. 30 Focused measurement of MR is suggested for accurate diagnosis and staging. 31, 32 The unified grading scheme is in alignment with the recent quantification of valvular regurgitation guidelines from the American Society of Echocardiography.
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Primary MR
In the updated 2017 valve guidelines, the majority of the recommendations for surgical or percutaneous intervention for patients with chronic, severe primary MR remain similar ( Table 5 ). The exception is the new recommendation that mitral valve (MV) surgery is reasonable for asymptomatic patients (stage C1) and preserved left ventricular (LV) size and function (LV ejection fraction >60% and LV end systolic dimension <40 mm) with a progressive increase in LV size or decrease in LV ejection fraction on serial imaging studies (Class IIa, LOE C-LD). This change is attributed to the realization that patients with severe MR who reach an ejection fraction ≤60% or LV end systolic dimension >40 mm have already developed LV systolic dysfunction. Watchful waiting has increasing come under scrutiny. 33 The increased volume load associated with MR can lead to a vicious cycle of LV dilation and deformation of the mitral apparatus, and microscopic fibrosis. A number of studies questioned the idea of waiting for typical surgical triggers. 34 Prospective analysis of 840 degenerative MV repair patients found that survival was near normal postoperative except in those with LV systolic dysfunction or New York Heart Association (NYHA) class IV symptoms. 35 A retrospective analysis of 4253 patients with primary degenerative MR associated any symptoms beyond NYHA class I with lower rates of survival. 36 When assessing registry data on 2097 patients with flail mitral leaflet and severe MR, early surgery was associated with reduced mortality and heart failure at 10 years compared with a match cohort. 37 Additionally, if patients presented with pulmonary hypertension or LV dilation before surgery, postoperative mortality was increased. 34 This increasing level of evidence has prompted the consideration for earlier intervention in the appropriate patients.
Secondary MR
The 2014 guidelines recognized that for secondary MR, the focus of treatment was to correct the underlying cause of the MR whenever possible. If this is attributed to LV dysfunction, goal-directed medical therapy and cardiac resynchronization therapy are class I indications. Management in secondary MR is challenging, given that the valve is structurally normal, and the underlying LV dysfunction is worsened by volume load from MR. Correcting the MR only alters 1 part of the disease and has shown limited effectiveness. The role of surgical intervention of secondary MR was restricted to those with NYHA class III/IV symptoms that persisted despite medical therapy (class IIb indication).
The 2017 updated guidelines have added a class IIa recommendation to choose chordal-sparing MV replacement over annuloplasty with repair, but with the caveat that this should be limited to those with chronic severe MR that persists despite goal-directed medical therapy (Table 6 ). This is heavily influenced by an RCT involving 251 patients with severe secondary MR who were randomized to MV repair versus replacement. 30, 38 The updated 2017 guidelines reflect the lack of clear benefit for repairing moderate MR in patients undergoing coronary artery bypass grafting (Table 6 ).
Prosthetic Valve Choice
Recognition of the strengths and limitations of different prosthetic valves, and the need to include patients on the III: harm B MVR should not be performed for the treatment of isolated severe primary MR limited to less than one half of the posterior leaflet unless mitral valve repair has been attempted and was unsuccessful.
From Nishimura et al. 4 Copyright 2017 American Heart Association, Inc. Used with permission. AF indicates atrial fibrillation; COR, class of recommendation; EF, ejection fraction; ESD, end systolic diameter; GDMT, goal-directed medical therapy; HF, heart failure; LD, limited data; LOE, level of evidence; LV, left ventricle; MR, mitral regurgitation; MVR, mitral valve repair; NYHA, New York Heart Association; NR, nonrandomized; R, randomized; TAVR, transcatheter aortic valve replacement; VHD, valvular heart disease. From Nishimura et al. 4 Copyright 2017 American Heart Association, Inc. Used with permission. AVR indicates aortic valve replacement; CABG, coronary artery bypass grafting; COR, class of recommendation; GDMT, goal-directed medical therapy; HF, heart failure; LOE, level of evidence; MR, mitral regurgitation; MVR, mitral valve repair; NYHA, New York Heart Association; R, randomized.
discussion regarding the risks and benefits of each valve type, remains highly emphasized in the 2017 updated guidelines. A careful discussion with the patient on the benefits of a bioprosthetic heart valve (BHV) versus a mechanical heart valve (MHV) remains a class I indication. However, longerterm follow-up on patients with prosthetic valves and new management options have been reflected in the 2017 updated guidelines (Table 7) .
A strong influencing factor when choosing the type of valve prosthesis is patient age. For those under 50, the 2017 updated guidelines provide a IIa recommendation for MHV in order to reduce the need for reoperation. For the very young, a pulmonary autograft could be considered (Class IIb). For those over 70, BHV are recommended (Class IIa). For those between the ages of 50 and 70, either mechanical or BHV could be I B Anticoagulation with a VKA to achieve an INR of 2.5 is recommended for patients with a mechanical bileaflet or current-generation single-tilting disc AVR and no risk factors for thromboembolism.
I B Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in patients with a mechanical AVR and additional risk factors for thromboembolic events (AF, previous thromboembolism, LV dysfunction, or hypercoagulable conditions) or an older-generation mechanical AVR (such as ball-in-cage).
I B Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in patients with a mechanical MVR. I A Aspirin 75 mg to 100 mg daily is recommended in addition to anticoagulation with a VKA in patients with a mechanical valve prosthesis.
IIa B Aspirin 75 mg to 100 mg per day is reasonable in all patients with a bioprosthetic aortic or mitral valve.
IIa B-NR Anticoagulation with a VKA to achieve an INR of 2.5 is reasonable for at least 3 months and for as long as 6 months after surgical bioprosthetic MVR or AVR in patients at low risk of bleeding.
IIb B-R A lower target INR of 1.5 to 2.0 may be reasonable in patients with mechanical On-X AVR and no thromboembolic risk factors.
IIb B-NR Anticoagulation with a VKA to achieve an INR of 2.5 may be reasonable for at least 3 months after TAVR in patients at low risk of bleeding.
IIb C Clopidogrel 75 mg daily may be reasonable for the first 6 months after TAVR in addition to lifelong aspirin 75 mg to 100 mg daily.
III: harm B Anticoagulant therapy with oral direct thrombin inhibitors or anti-Xa agents should not be used in patients with mechanical valve prostheses.
considered with patient preference or risk factors (need for anticoagulation, bleeding risk) weighing in the discussion (Class IIa).
Multiple randomized trials and observational studies have been published on valve selection. Consistently, BHV carry a higher risk of reoperation, primarily attributed to valve failure, most prominently beyond the 10-to 12-year mark. 41, 42 When comparing a 15-year outcomes, survival and stroke risk were relatively similar regardless of valve choice. However, BHV was associated with a higher rate of reoperation (12.1%; CI 6.2-11 versus 6.9; CI, 4.2-9.6), but lower major bleeding (6.6%; CI 4.8-8.4 versus 13.0; CI, 9.9-16.1). 43 A prospective cohort followed 310 patients randomized to BHV versus MHV out to 108AE28 months and showed no difference in mortality, bleeding, or valve thrombosis, but with significant increases in valve failure (P=0.0001) and need for reoperation (P=0.0003). 44 A RCT including veterans showed increased mortality in aortic BHV over MHV, primarily attributed to valve failure. 41 Added to the modern discussion of valve choice is the potential for transcatheter valve-in-valve (VIV) procedures. Though the published data are limited in this group so far, the Valve-In-Valve International Database registry has published on 459 patients undergoing VIV procedures for bioprosthetic valve failure. Success rates are reasonable, with 93% survival at 30 days and significant improvement in functional class (to class I/II). 45, 46 One-year survival rates were 83%, and factors that were associated with mortality included a small surgical prosthesis (21 mm) and prosthetic stenosis as the primary indication for intervention (rather than regurgitation). 45 These new data allow for additional topics of discussion when deciding on type of prosthesis with patients who need valve surgery aged between 50 and 70 years.
Prosthetic Valve Antithrombotic Therapy
Recommendations for anticoagulation strategies for prosthetic heart valves remains similar between the 2014 valve guidelines and the 2017 updated guidelines with a few exceptions (Table 8) . Anticoagulation in patients with a mechanical heart is based on the monitored use of VKA with international normalized ratio (INR) ranges targeted based on factors that affect thrombogenic potential. 3.0. Use of low-dose aspirin is also recommended because it has found to reduce the residual risk of stroke for a small increase in bleeding risk. Additionally, acetylsalicylic acid continues to be reasonable for BHV for lifelong thromboembolic prophylaxis (Class IIa). Anticoagulation with a VKA to achieve an INR of 2.5 for at least 3 months and for as long as 6 months after surgical bioprosthetic MV replacement and AVR in patients with a low risk of bleeding remains a class IIa recommendation, but the level of evidence has been upgraded from C to B-NR. This change is supported by the increased rate of thromboembolism, presumed to be related to implanted material until endothelialization occurs. TAVR valves are managed differently, because the early trials had used dual antiplatelet agents with acetylsalicylic acid and clopidogrel 75 mg for 6 months postinsertion. Finally, there is now a Class III recommendation for DOACs in mechanical valves because increased rates of mechanical valve thrombosis were noted with these agents. As TAVR use expanded and new data became available, increased recognition of clinical and subclinical leaflet thrombus was detected ( Figure 3A and 3B) . With imaging data from TAVR trials, reduced leaflet motion was observed in 7% to 40% of TAVR patients, [47] [48] [49] [50] though clinically evident effects were rare (1%). 50 VKA usage was found to effectively treat thrombosis. [48] [49] [50] Additionally, those who were on VKAs for other reasons had significantly lower rates of valve thrombosis (10.7% versus 1.8%; relative risk, 6.09; 95% CI, 1.86-19.84). 48, 50 Because of these data, VKA is considered reasonable for at least 3 months post-TAVR in low-bleedingrisk patients.
A new, lower targeted INR was included for a specific mechanical AVR, the On-X valve. A single randomized trial with 375 patients compared a regimen of acetylsalicylic acid for all, INR 2.0 to 3.0 for 3 months, and then either targeting an INR of 1.5 to 2.0 or 2.0 to 3.0. There was an increased rate of major bleeding in the standard INR group (3.26% versus 1.48%; P=0.047), with no significant difference in thrombotic events (relative risk, 1.6; 95% CI, 0.81-3.17; P=0.178) observed early on in this small trial. 51 
Bridging Therapy for Prosthetic Valves
For patients with MHV who had scheduled procedures, the 2014 valve guidelines recommendations were based on opinions and limited retrospective data. These recommendations included continuing anticoagulation for minor procedures, temporary interruption for bileaflet mechanical aortic valves without other risk factors, and bridging with heparinoids for others with mechanical prosthesis.
Although the BRIDGE (Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery) trial excluded MHV, From Nishimura et al. 4 Copyright 2017 American Heart Association, Inc. Used with permission. CAD indicates coronary artery disease; NYHA, New York Heart Association. I B-NR Urgent initial treatment with either slow-infusion low-dose fibrinolytic therapy or emergency surgery is recommended for patients with a thrombosed left-sided mechanical prosthetic heart valve presenting with symptoms of valve obstruction. Journal of the American Heart Association this randomized trial assigned patients on chronic anticoagulation to receive low-molecular-weight heparin versus placebo for bridging before elective surgery and found no significant difference in arterial thromboembolism, but a significant increase in major bleeding (relative risk, 0.41; CI, 0.20-0.78). This study raised concerns that by bridging with overlapping anticoagulation agents can increase bleeding risk without reducing risk of thromboembolism. In light of this evidence, the recommendation for bridging has been altered from I, LOE C, to a level IIa, LOE C-LD (Table 9 ).
Prosthetic Valve Thrombosis
Obstruction of MHV and BHV can occur from either pannus growth or thrombus formation, or both. The 2014 guidelines recognized challenges in diagnosis. Transthoracic echo was a class I indication for assessment of severity and monitoring for resolution of thrombosis, with transesophageal echo for assessing valve motion and thrombus size (Class Ia; Figure 4A and 4B) and computed tomography or fluoroscopy used for adjunctive assessment (Class IIa).
Valve obstruction can be difficult to classify by transthoracic echo alone. The 2017 updated guidelines suggest urgent multimodality imaging for thorough assessment of valve function, leaflet motion, and to assess for the presence and size of thrombus (Class I; Table 10 ). Increasingly, the recognition for each modality's strengths and weaknesses should be taken into account for a complete assessment. Transthoracic echo provides prompt availability and excellent hemodynamic assessment, but the views of valve motion are often limited. 52 Transesophageal echo can better assess valve motion, and thrombus or pannus formation and differentiation. 53, 54 Additionally, prosthetic shadowing on transesophageal echo can limit assessment of aortic valves. 55 Computed tomography can differentiate thrombus from pannus as well as assess thrombus size and valve motion. 56, 57 Cinefluoroscopy has excellent ability to visualize valve motion for both diagnosis and treatment. 52, 58 In the 2014 guidelines, medical management of valve thrombus was limited to recent onset (<14 days), NYHA class I to II, and small thrombus (<0.8 cm 2 ) or for right-sided thrombosis. Surgery was often the first and only option. Increasingly, thrombolytic therapy has been incorporated into clinical practice. Various regimens from ultrarapid to low-dose continuous infusion have been attempted. [59] [60] [61] [62] [63] [64] [65] Ozkan showed efficacy and increased safety with an echo-guided, no-bolus, low-dose, slow-infusion regimen, 60 and analysis of 114 patients treated with 1 or more sessions showed a high rate of success (90%) and low rate of complications (embolism 1.7%, major bleed 1.7%, and minor bleed 1.7%).
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The decision on management of this condition is complex. The 2017 updated guidelines provide a Class I recommendation for urgent therapy with either slow-infusion, low-dose fibrinolytics or emergency surgery diagnosis and consideration of patient-and site-specific factors (Table 11) .
Prosthetic Valve Stenosis and Regurgitation
Before modern percutaneously implantable valves, options for management of prosthetic valve stenosis and regurgitation were limited. In valvular stenosis, surgical replacement was essentially the exclusive intervention. These patients were not only higher risk because of increased age and IIa B-NR For severely symptomatic patients with bioprosthetic aortic valve stenosis judged by the heart team to be at high or prohibitive risk of reoperation, and in whom improvement in hemodynamics is anticipated, a transcatheter valve-in-valve procedure is reasonable.
IIa B-NR For severely symptomatic patients with bioprosthetic aortic valve regurgitation judged by the heart team to be at high or prohibitive risk for surgical therapy, in whom improvement in hemodynamics is anticipated, a transcatheter valve-in-valve procedure is reasonable.
From Nishimura et al. 4 Copyright 2017 American Heart Association, Inc. Used with permission. COR indicates class of recommendation; HF, heart failure; LD, limited data; LOE, level of evidence; NYHA, New York Heart Association; NR, nonrandomized; VKA, vitamin K antagonist.
repeat surgery, but also multiple surgical procedures were often combined. 66 In the 2017 updated guidelines, surgery remains a Class I indication for operable patients with severe symptomatic prosthetic valve stenosis and for operable patients with MHV with intractable hemolysis or heart failure attributed to severe prosthetic or paraprosthetic regurgitation (Table 12) . Surgery is also reasonable for asymptomatic patients with acceptable operative risk with severe BHV regurgitation (Class IIa, LOE C-LD [updated from LOE C]).
At the time of publication of the 2014 guidelines, BHV thrombosis was not well appreciated. Bioprosthetic valve thrombosis presents differently and is dealt with differently than mechanical valves. In general, VKAs are not continued in bioprosthesis patients without risk factors for thrombosis postsurgery. Historically, bioprosthetic valve thrombus is rare (0.5% in aortic position and 6% in mitral). However, in modern registry data with routine multimodality surveillance, aortic thrombus was identified in 14% of TAVR and 7% of SAVR patients. 48 Symptoms, ranging from heart failure to stroke, remained rare (0.37-1%). 48, 67 With the availability of transcather-based valve therapies came alternatives to open surgical valve replacement. 68 The
Valve-In-Valve International Database registry has collected data on the use of transcatheter-based VIV procedures. Data from the registry showed a 1-year survival rate of 83%, with the majority of survivors having a significant symptom improvement (92% NYHA class I-II). 45 A systematic review assessed 823 patients with transcatheter VIV procedure or surgical redo AVR. 69 The VIV patients were older and had more comorbidities. Regardless, periprocedural mortality was similar (VIV 7.9% versus AVR 6.1%; P=0.35), with significantly less stroke (1.9% versus 8.8%; P=0.002) and major bleeding (6.9% versus 9.1%; P=0.014) though higher paravalvular leak From Nishimura et al. 4 Copyright 2017 American Heart Association, Inc. Used with permission. COR indicates class of recommendation; IE, infective endocarditis; HF, heart failure; LD, limited data; LOE, level of evidence; NR, nonrandomized.
rates (3.3% versus 0.4%; P=0.022). Interestingly, transvalvular gradients were not significantly different between groups (15.2 versus 13.5 mm Hg; P=0.55). Benefit has been noted in patients with stenosis, regurgitation, or mixed disease. Careful assessment of both the valve and patient factors for consideration of the VIV procedure has been added to the 2017 updated guidelines for both bioprosthetic stenosis and regurgitation with a Class IIa indication (Table 12) .
Bioprosthetic thrombus can present as increased leaflet thickening with restricted leaflet motion and increased valve gradients. 70 This occurs much earlier than valve degeneration, most commonly identified at 1 to 2 years, though reported out to 6.5 years. 67, 70 With VKA treatment, most patients experience resolution of thrombus, as well as hemodynamic and symptom improvement. 48, 67, 70 In the 2017 updated guidelines, patients with suspected or confirmed BHV thrombosis who are hemodynamically stable and have no contraindications for anticoagulation should be treated with VKA (Class IIa; Table 12 ).
The recommendation for transcatheter-based therapies noted in the 2014 guidelines as a potential treatment option for paravalvular regurgitation (Class IIa) for patients with high operative risk and intractable class III/IV heart failure or hemolysis, remains unchanged in the 2017 updated guidelines.
Infective Endocarditis
Endocarditis continues to be a major clinical problem with prohibitive mortality rates. The 2014 valve guidelines provided extensive guidance for management in the acute phase of the illness, including aggressive antibiotic therapy, early removal of devices, and surgical consultation with consideration on timing of surgery, should any be required. These recommendations remain unchanged in the 2017 updated guidelines (Table 13) .
The 2017 updated guidelines address the timing of operation in patients with IE who have suffered a stroke. For left-sided endocarditis, neurological complications are common (17-25%) 7, 71 and associated with significant mortality (45% with versus 24% without neurological event). 71 A previous retrospective study observed that patients with embolic stroke had lower rates of cerebral complications if surgery was delayed more than 4 weeks (10% at 2-4 weeks and 2.3% at >4 weeks). 72 However, these early observational data were not risk adjusted. A more-recent retrospective analysis of patients with IE complicated by ischemic stroke included risk-adjusted analysis. 73 In this small study, 198
patients underwent valve replacement surgery with 58 undergoing surgery within 7 days poststroke. The risk for in-hospital mortality (odds ratio, 2.308; 95% CI, 0.94-5.65) or 1-year mortality (hazard ratio, 1.138; 95% CI, 0.80-1.65) was not significantly different between the 2 groups. Another observational study of 1345 patients showed that in patients with a hemorrhagic neurological event, mortality was prohibitive for those having surgery within 4 weeks (75%) and elevated, but slightly lower, for those after 4 weeks (40%). 71 As a result of these studies, the 2017 updated guidelines recommend operation without delay for those patients with IE who need cardiac surgery and have suffered a stroke but have no intracranial hemorrhage or extensive neurological damage (Class IIb, LOE B-NR) ( Table 13 ).
Conclusion
The 2017 updated AHA/ACC valve guidelines provide treatment recommendations based on new data compiled since the 2014 document. Similar in both documents is the importance of including the patient as an active participant in the decision-making process. Stages of disease and involvement of the heart valve team also remain unchanged. New options for treatment, particularly percutaneous modalities now offer patients more choices. The 2017 updated guidelines highlight the established and novel treatments with defined levels of recommendation and strength of evidence to aid healthcare providers in navigating the complex options now available to treat VHD.
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